Overview

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Status:
RECRUITING

Trial end date:
2029-03-15

Target enrollment:

Participant gender:

Summary

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Phase:

PHASE1

Details

Lead Sponsor:

Cullinan Therapeutics Inc.